2025 Global Biosimilar Contract Manufacturing Market Revenue Opportunities Report
Description
The 2025 Global Biosimilar Contract Manufacturing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Biosimilar Contract Manufacturing Market are Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza, Catalent, Inc., and Biocon. Boehringer Ingelheim operates its BioXcellence unit, providing end-to-end biosimilar manufacturing, including DNA to fill-finish solutions, with expertise in mammalian cell cultures and microbial fermentation. Lonza is a key global player offering extensive contract manufacturing biosimilar services, focusing on scalable biologics production. Catalent, Inc. specializes in comprehensive development and manufacturing solutions, playing a major role in biosimilar CDMO services. Biocon, based in India, leverages state-of-the-art facilities in India and Malaysia to produce biosimilars, especially monoclonal antibodies and insulin analogues, addressing global therapeutic areas such as oncology and diabetes.
In addition to these companies, the market is strongly influenced by regional growth dynamics. North America leads due to advanced infrastructure and regulatory expertise, with many small and mid-size biotech firms outsourcing production. Asia-Pacific shows rapid growth fueled by cost-effectiveness and skilled labor, with Indian firms like Biocon emphasizing innovation and manufacturing capacity. South Korean companies such as Samsung Biologics and Celltrion are also prominent in biosimilar manufacture and contract development, enhancing global biosimilar access and capacity. Strategic partnerships and collaborations, such as Boehringer Ingelheim's 2024 alliance with Quallent Pharmaceuticals, highlight the trend toward expanding biosimilar availability and improving healthcare affordability worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Biosimilar Contract Manufacturing Market are Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza, Catalent, Inc., and Biocon. Boehringer Ingelheim operates its BioXcellence unit, providing end-to-end biosimilar manufacturing, including DNA to fill-finish solutions, with expertise in mammalian cell cultures and microbial fermentation. Lonza is a key global player offering extensive contract manufacturing biosimilar services, focusing on scalable biologics production. Catalent, Inc. specializes in comprehensive development and manufacturing solutions, playing a major role in biosimilar CDMO services. Biocon, based in India, leverages state-of-the-art facilities in India and Malaysia to produce biosimilars, especially monoclonal antibodies and insulin analogues, addressing global therapeutic areas such as oncology and diabetes.
In addition to these companies, the market is strongly influenced by regional growth dynamics. North America leads due to advanced infrastructure and regulatory expertise, with many small and mid-size biotech firms outsourcing production. Asia-Pacific shows rapid growth fueled by cost-effectiveness and skilled labor, with Indian firms like Biocon emphasizing innovation and manufacturing capacity. South Korean companies such as Samsung Biologics and Celltrion are also prominent in biosimilar manufacture and contract development, enhancing global biosimilar access and capacity. Strategic partnerships and collaborations, such as Boehringer Ingelheim's 2024 alliance with Quallent Pharmaceuticals, highlight the trend toward expanding biosimilar availability and improving healthcare affordability worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
